ROQAF (Roquefort Therapeutics) Total Liabilities : $1.46 Mil (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics Total Liabilities?

Roquefort Therapeutics's Total Liabilities for the quarter that ended in Jun. 2024 was $1.46 Mil.

Roquefort Therapeutics's quarterly Total Liabilities declined from Jun. 2023 ($0.82 Mil) to Dec. 2023 ($0.75 Mil) but then increased from Dec. 2023 ($0.75 Mil) to Jun. 2024 ($1.46 Mil).

Roquefort Therapeutics's annual Total Liabilities increased from Dec. 2021 ($0.63 Mil) to Dec. 2022 ($0.69 Mil) and increased from Dec. 2022 ($0.69 Mil) to Dec. 2023 ($0.75 Mil).

Roquefort Therapeutics Total Liabilities Historical Data

The historical data trend for Roquefort Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Total Liabilities Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Liabilities

0.63

0.69

0.75

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Liabilities	Get a 7-Day Free Trial			1.70	0.69	0.82	0.75	1.46

Roquefort Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Roquefort Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.389	+	(0	+	0.357
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.75

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	7.708	-	6.962
	=	0.75

Roquefort Therapeutics's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.098	+	(0	+	0.359
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.46

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	7.728	-	6.271
	=	1.46

Roquefort Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ROQ:UK

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

From GuruFocus

Roquefort Therapeutics PLC at OTC Markets Life Science Investor Forum (Virtual) Transcript

By GuruFocus Research • 03-27-2024